Literature DB >> 27165295

Successful hematopoietic stem cell mobilization with vinorelbine and filgrastim in germ cell tumor.

Fabiana Aguiar Carneiro-Silva1, Denise Menezes Brunetta2,3, Jacques Kaufman2, João Paulo Vasconcelos Leitão2, Karine Sampaio Nunes Barroso2, Suzanna Araújo Tavares Barbosa3, Luciana Maria de Barros Carlos3, Fernando Barroso-Duarte2.   

Abstract

Germ cell tumor (GCT) is the most frequent cancer in young men and is highly curable. Almost 80 % of patients with the disease in an advanced stage achieve a reliable response to cisplatin combination chemotherapy. For relapsing or refractory disease, autologous hematopoietic stem cell transplantation (HSCT) is an effective therapy. The two most used mobilization strategies for HSC collection are filgrastim alone or filgrastim after chemotherapy (chemomobilization). HSC collection with filgrastim mobilization can be difficult, especially in highly treated patients. While the addition of chemotherapy improves mobilization and reduces the number of apheresis sessions, it can increase morbidity rate as well. We describe a case of a 45-year-old male with classical seminoma who was submitted to orchiectomy. Two months after, he presented progression of the tumor. He received four cycles of cisplatin, etoposide and bleomycin, with residual retroperitoneal mass and cervical lymphadenopathy. Further, he was submitted to three more cycles of cisplatin, ifosfamide and paclitaxel. Thereupon, he showed partial response. At that moment, autologous HSC transplantation was considered. In the first mobilization, filgrastim alone was used without success in harvesting. The second mobilization consisted of vinorelbine at day 1 (35 mg/m2) and filgrastim (16 µg/kg) started at day 5. The peak of CD34+ cells in peripheral blood was 32.6 × 106 cells/L on day 8, with 4.73 × 106 cells/kg CD34+ collected on days 8 and 9. The benefits of this scheme include: (a) outpatient administration, (b) fewer doses of filgrastim, (c) minimal risk of febrile neutropenia and (d) reliable prediction of collection day. For these reasons, we conclude that vinorelbine chemomobilization is a great option for GCT, particularly in patients with high risk of mobilization failure. Furthermore, it requires less resource usage, hospitalizations and transfusions than conventional chemomobilization.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27165295     DOI: 10.1007/s10238-016-0425-2

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  7 in total

1.  Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective.

Authors:  M J Bargetzi; J Passweg; E Baertschi; A Schoenenberger; C Gwerder; A Tichelli; J Burger; W Mingrone; R Herrmann; A Gratwohl; M Wernli
Journal:  Bone Marrow Transplant       Date:  2003-01       Impact factor: 5.483

2.  Importance of surgery as salvage treatment after high dose chemotherapy failure in germ cell tumors.

Authors:  A Fléchon; M Rivoire; P Biron; J P Droz
Journal:  J Urol       Date:  2001-06       Impact factor: 7.450

3.  Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.

Authors:  Panagiotis Samaras; Sarah Pfrommer; Burkhardt Seifert; Ulf Petrausch; Axel Mischo; Adrian Schmidt; Urs Schanz; Gayathri Nair; Mario Bargetzi; Christian Taverna; Roger Stupp; Frank Stenner-Liewen; Christoph Renner
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-30       Impact factor: 5.742

Review 4.  Improving stem cell mobilization strategies: future directions.

Authors:  W Bensinger; J F DiPersio; J M McCarty
Journal:  Bone Marrow Transplant       Date:  2009-01-12       Impact factor: 5.483

5.  High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.

Authors:  Lawrence H Einhorn; Stephen D Williams; Amy Chamness; Mary J Brames; Susan M Perkins; Rafat Abonour
Journal:  N Engl J Med       Date:  2007-07-26       Impact factor: 91.245

6.  Efficient mobilization of PBSC with vinorelbine/G-CSF in patients with malignant lymphoma.

Authors:  M Heizmann; A C O'Meara; P R Moosmann; I A F M Heijnen; M Zuberbühler; P Fernandez; J Burger; A Huber; M Wernli; M J Bargetzi
Journal:  Bone Marrow Transplant       Date:  2009-01-26       Impact factor: 5.483

7.  Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.

Authors:  P J Loehrer; R Gonin; C R Nichols; T Weathers; L H Einhorn
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.